Advanced heart failure

• Disease Description (Causes and Symptoms)

  • Definition summary: Advanced heart failure refers to a condition (Stage D in guidelines) in which symptoms do not improve or repeatedly worsen despite standard drug and device therapy, such that heart transplantation or long-term mechanical circulatory support devices (such as LVADs), inotropes, renal replacement therapy, or palliative care (hospice·palliative) may be considered.
  • Main causes and pathophysiology:
    • As chronic myocardial diseases (ischemic heart disease, dilated cardiomyopathy, etc.) progress, cardiac output and compensatory capacity decline. Persistent cardiac systolic and diastolic dysfunction and overactivation of neuroendocrine compensatory mechanisms (the sympathetic nervous system and renin–angiotensin system) lead to end-stage deterioration of cardiac function.
    • Through repeated exacerbations (including hospitalization and the need for intravenous diuretics), systemic organs such as the kidneys, liver, lungs, and muscles are affected.
  • Main symptoms:
    • Persistent dyspnea even at rest or during low-level activity (primary symptom), inability to exercise, peripheral edema, fatigue·malaise, nocturnal dyspnea·sleep apnea, and weight changes (edema·cachexia).
    • Functional indicator: NYHA class 3–4 (symptoms worsen even with activity below the level of usual daily activities).

• Treatment Methods

  • Diagnostic tests (essential for treatment decisions): echocardiography, cardiac catheterization (measurement of intracardiac pressure, pulmonary artery pressure, and pulmonary vascular resistance), cardiopulmonary exercise testing (CPET), BNP/NT‑proBNP, kidney·liver·electrolyte tests, electrolytes·electrocardiography, and, when necessary, myocardial biopsy.
  • Drug therapy (based on the latest guidelines):
    • Foundational therapy: consider an ARNI (sacubitril/valsartan) first (if there are no contraindications), or an ACE inhibitor/ARB
    • Beta-blockers (bisoprolol, metoprolol succinate, carvedilol, etc.)
    • MRA (spironolactone, eplerenone, etc.)
    • SGLT2 inhibitors (dapagliflozin, empagliflozin) — reduce mortality·hospitalization in patients with heart failure
    • Diuretics (loop diuretics: furosemide, etc.) for fluid management
    • When symptoms or cardiac function worsen: consider short-term use of intravenous inotropes (dobutamine, milrinone)
    • Adjunctive medications: ivabradine (heart-rate control), nitrates/hydralazine (in selected patients), anticoagulation (when indicated)
  • Device·procedural·surgical treatment:
    • Primary device therapy: ICD (therapeutic defibrillation), CRT (cardiac resynchronization therapy) — when indicated
    • End-stage treatment options:
      • Heart transplantation (evaluation of eligibility and contraindications is required)
      • Long-term durable left ventricular assist device (LVAD): bridge-to-transplant or destination therapy
    • Intensive treatment with prompt hospitalization: intravenous diuretics, inotropes, renal replacement therapy (when uremia·fluid management is required)
  • Palliative care:
    • Symptom-focused palliative care, establishing quality-of-life goals for patients with end-stage disease, and considering referral to hospice
  • Lifestyle management (self-management·prevention):
    • Low-salt diet (the general recommendation of no more than 2 g of Na per day should be individualized), fluid restriction (as directed by a physician), daily weight measurement·recording, regular medication use, smoking cessation·moderation of alcohol, regular vaccinations (influenza·pneumococcal), and nutrition·exercise when necessary (individualized rehabilitation)
  • Treatment precautions·risk of complications:
    • Medication adverse effects: monitoring is required for hypotension, worsening kidney function, hyperkalemia, etc.
    • LVAD/transplant-related: infection, bleeding, thrombosis/stroke, device failure, and adverse effects of immunosuppressants (transplantation)
    • Progressive heart failure carries a risk of complications such as multiorgan failure, tachyarrhythmia, kidney failure, abnormal liver function, and malnutrition

• Pre-Outpatient Visit Checklist (Including Sample Questions)

  • Items to prepare (recommended to bring):
    • Complete list of currently used medications (including doses·administration times), recent test results (blood tests, BNP/NT‑proBNP, kidney function), recent echocardiography·cardiac catheterization results·prescriptions, weight log (most recent 1–2 weeks), and history of hospitalization·emergency department visits
    • Symptom diary: timing·frequency of dyspnea, aggravating factors, location of edema·when it worsens, changes in urine output, and exercise capacity (walking distance·ability to climb stairs)
    • Changes in activity·diet (food·salt·fluid intake), and medications to avoid or contraindicated medications (including OTC·herbal medicines)
  • Key information to provide to the doctor during the outpatient visit:
    • Recent weight changes (daily·total change), when edema·dyspnea recently worsened, and whether there has been recent hospitalization·administration of intravenous diuretics
  • Examples of questions to ask yourself during the outpatient visit (think about them before the appointment):
    • What signs mean that I should contact the doctor immediately or visit the emergency department if my symptoms worsen?
    • Which of the medications I am taking must not be stopped?

• Examples of General Questions to Ask the Doctor

  • What are the main adverse effects and monitoring requirements of this medication (e.g., an ARNI/beta-blocker/SGLT2 inhibitor)?
  • What is my prognosis given my current condition (test results·NYHA class), and what are the treatment goals (survival·quality of life)?
  • How is eligibility for heart transplantation or an LVAD evaluated, and what are the approximate waiting time·expected risks?
  • What precautions should I take in daily life (exercise·travel·driving·sexual activity)?

• Examples of Disease-Specific Questions (1–2)

  • "Could you explain specifically whether I am a candidate for heart transplantation and which option is realistic for me—bridge-to-transplant or destination therapy with an LVAD?"
  • "Based on my recent tests (echocardiography·cardiac catheterization results), is medication adjustment necessary (e.g., starting·increasing an ARNI, introducing an SGLT2 inhibitor, or changing the diuretic dose)? If so, what are the expected benefits and risks?"

Additional reference (clinical context): Advanced heart failure may have a poor prognosis, with a reported 1-year survival rate of approximately 84% and a 5-year survival rate of approximately 66% when hospitalization is required. Therefore, early·intensive evaluation and treatment strategies (medication optimization·device therapy·transplant evaluation) at a specialized heart failure center are important.